199 related articles for article (PubMed ID: 22685431)
1. Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Laffin B; Petrash JM
Front Pharmacol; 2012; 3():104. PubMed ID: 22685431
[TBL] [Abstract][Full Text] [Related]
2. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Hojnik M; Frković Grazio S; Verdenik I; Rižner TL
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614
[TBL] [Abstract][Full Text] [Related]
3. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
4. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.
Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076
[TBL] [Abstract][Full Text] [Related]
5. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
6. Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.
Reddy KA; Kumar PU; Srinivasulu M; Triveni B; Sharada K; Ismail A; Reddy GB
Breast; 2017 Feb; 31():137-143. PubMed ID: 27855345
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductases in the eye.
Huang SP; Palla S; Ruzycki P; Varma RA; Harter T; Reddy GB; Petrash JM
J Ophthalmol; 2010; 2010():521204. PubMed ID: 20628518
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.
Saeed A; Ejaz SA; Sarfraz M; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807227
[TBL] [Abstract][Full Text] [Related]
11. Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Hevir N; Sinkovec J; Lanišnik Rižner T
Chem Biol Interact; 2013 Feb; 202(1-3):226-33. PubMed ID: 23146748
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
13. In-silico Investigations of quinine and quinidine as potential Inhibitors of AKR1B1 and AKR1B10: Functional and structural characterization.
Ejaz SA; Saeed A; Birmani PR; Katubi KM; Elqahtani ZM; Al-Buriahi MS; Ujan R; Siddique F; Ahmed SB; Alrowaili ZA
PLoS One; 2022; 17(10):e0271602. PubMed ID: 36301939
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Chen W; Chen X; Zhou S; Zhang H; Wang L; Xu J; Hu X; Yin W; Yan G; Zhang J
Steroids; 2016 Jun; 110():1-8. PubMed ID: 26968129
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
[TBL] [Abstract][Full Text] [Related]
16. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
17. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
18. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
[TBL] [Abstract][Full Text] [Related]
20. Decoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition.
Liu M; Qin X; Li J; Jiang Y; Jiang J; Guo J; Xu H; Wang Y; Bi H; Wang Z
Phys Chem Chem Phys; 2024 Mar; 26(12):9295-9308. PubMed ID: 38469695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
